SCHEMBL6985104

SCHEMBL6985104

CCOC(=O)C1C=Nc2c(cc(F)cc2[N+](=O)[O-])C1=O

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.38
ALDH1A1 P00352 5/20 0.36
MEN1 O00255 2/20 0.36
HPGD P15428 2/20 0.36
KMT2A Q03164 2/20 0.36
KDM4E B2RXH2 1/20 0.36
GAA P10253 1/20 0.36
HSD17B10 Q99714 1/20 0.36
SMN1; SMN2 Q16637 3/20 0.34
VCAM1 P19320 1/20 0.33
TP53 P04637 1/20 0.33
HTT P42858 1/20 0.33
GPR174 Q9BXC1 2/20 0.33
MITF O75030 2/20 0.33
CYP1A2 P05177 1/20 0.33
CYP2C9 P11712 1/20 0.33
CYP2C19 P33261 1/20 0.33
GALR2 O43603 1/20 0.33
LMNA P02545 1/20 0.33
POLB P06746 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10382766 0.83 ALDH1A1 (0.38) MAPTALDH1A1MEN1HPGDKMT2A
SCHEMBL6974946 0.83 MAPT (0.40) MAPTALDH1A1MEN1HPGDKMT2A
SCHEMBL6982236 0.82 TTR (0.33)
SCHEMBL7225483 0.72 ALDH1A1 (0.35) MAPTALDH1A1MEN1HPGDKMT2A
SCHEMBL29007923 0.72 CDC7 (0.40) MAPTALDH1A1MEN1HPGDKMT2A
SCHEMBL7220460 0.71 ALDH1A1 (0.40) MAPTALDH1A1MEN1HPGDKMT2A
SCHEMBL6981252 0.69 L3MBTL1 (0.38) MAPTALDH1A1MEN1HPGDKMT2A
SCHEMBL2649285 0.68 RAB9A (0.48) MAPTALDH1A1GAASMN1; SMN2HTT
SCHEMBL30417731 0.68 KMT2A (0.36) MAPTALDH1A1MEN1HPGDKMT2A
SCHEMBL5782427 0.67 TDP2 (0.50) MAPTALDH1A1MEN1HPGDKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1027351-B1 PHENANTHROLINE DERIVATIVES FIBROGEN INC (US) 2003-12-03 EP disclosed
US-20010001101-A1 Phenanthroline derivatives ZENECA LIMITED 2001-05-10 US disclosed
US-6200974-B1 FOR PRODUCING AN ANTI-FIBROPROLIFERATIVE EFFECT ZENECA LIMITED (GB) 2001-03-13 US disclosed
EP-1027351-A1 PHENANTHROLINE DERIVATIVES FIBROGEN, INC. (US) 2000-08-16 EP disclosed
US-5916898-A ANTIFIBROPROLIFERTIVE, ENZYME INHIBITORS OF PYROLYL 4-HYDROXYLASE, ANTIARTHRITIC AGENTS ZENECA LIMITED (GB) 1999-06-29 US disclosed
WO-1999021860-A1 PHENANTHROLINE DERIVATIVES FIBROGEN, INC. (US) 1999-05-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010001101-A1 Phenanthroline derivatives H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, COL1A1, COL2A1 MAPT 4808/4885ALDH1A1 425/4885MEN1 2187/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.